We established a diversified and comprehensive R&D pipeline covering oncology, autoimmune diseases, pain management, cardiovascular diseases, metabolic diseases, infectious diseases, …

Jul 10, 2025 · Jiangsu Hengrui Pharmaceuticals is a rare blend of innovation and execution. Its pipeline diversification across oncology, cardiovascular, and metabolic therapies, paired with strategic …

May 7, 2025 · Herein, we presented a novel HER3×c-Met bispecific ADC, SDP01873, which exhibited excellent in vitro activity and superior efficacy in xenograft models. Methods: We used a site-specific …

Feb 17, 2025 · Hengrui has emerged as a leading force in ADC drug development, with a deep pipeline of 12 ADC drugs in clinical trials. Its proprietary HRMAP® platform and strategic innovations in …

2 days ago · So, the question is, what kind of ADC layout strategy does Hengrui use to create a rich R&D pipeline? In the highly competitive ADC track, can this former "pharmaceutical brother" win a …

盛迪医药是一家从事创新和高品质药品研制及推广的民族制药企业，已发展成为国内知名的抗肿瘤药、手术用药和影像介入产品的供应商。 2020年，公司入选全球投行Torreya公布的全球1000强药企榜 …

May 28, 2025 · Hengrui Medicine has extensive layout in four major fields: tumors, metabolic and cardiovascular diseases, immune and respiratory diseases, and neuroscience.

Jul 25, 2023 · Looking at the pipeline of Jiangsu Hengrui Pharmaceutical Group Co. Ltd., it is evident that the company has a robust and active pipeline. The majority of drugs are in the discovery phase, …

Our approach ensures a virtuous cycle in which each batch of approved drugs is immediately followed by another in clinical trials and yet another in the pipeline.

Nov 3, 2025 · Hengrui Oncology has established a robust and diversified oncology pipeline encompassing multiple tumor types, with a comprehensive portfolio that includes immunotherapies, …